[1]周诗银 吴强.新型冠状病毒肺炎与心血管系统疾病[J].心血管病学进展,2021,(11):982-985.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　ZHOU Shiyin,WU Qiang.Coronavirus Disease 2019 and Cardiovascular System Diseases[J].Advances in Cardiovascular Diseases,2021,(11):982-985.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
点击复制

新型冠状病毒肺炎与心血管系统疾病()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年11期
页码:
982-985
栏目:
综述
出版日期:
2021-11-25

文章信息/Info

Title:
Coronavirus Disease 2019 and Cardiovascular System Diseases
文章编号:
202005073
作者:
周诗银 吴强
(贵州省人民医院心内科,贵州 贵阳 550002)
Author(s):
ZHOU Shiyin; WU Qiang
(Department of Cardiology,Guizhou Provincial People’s Hospital,Guiyang 550002,Guizhou,China)
关键词:
新型冠状病毒肺炎; 严重急性呼吸综合征冠状病毒2; 心血管疾病
Keywords:
Coronavirus disease 2019; Severe acute respiratory syndrome coronavirus 2; Cardiovascular diseases
DOI:
10.16806/j.cnki.issn.1004-3934.2021.11.000
摘要:
新型冠状病毒肺炎是一种急性呼吸系统传染性疾病，目前已证实其可累及全身多个系统，以心血管系统受累最为常见，主要表现为心律失常、心力衰竭、急性心肌炎和心肌梗死等。有基础心血管疾病者罹患新型冠状病毒肺炎后重症比例更高，死亡风险更大。现对新型冠状病毒肺炎合并心血管系统疾病及其心血管并发症进行综述。
Abstract:
Coronavirus Disease 2019(COVID-19) is an acute respiratory infectious disease that has been confirmed to affect multiple systems of the body,in which the cardiovascular system is the most commonly involved, mainly manifested as arrhythmias,heart failure,acute myocarditis and myocardial infarction. Patients with cardiovascular diseases have a higher proportion of severe cases and a greater risk of death after suffering from COVID-19. This article reviews COVID-19 combined cardiovascular diseases and its cardiovascular complications

参考文献/References:

[1] Wrapp D,Wang N,Corbett KS,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science,2020,367(6483):1260-1263.

[2] Richardson S,Hirsch JS,Narasimhan M,et al. Presenting characteristics, comorbidities,and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area[J]. JAMA,2020,323(20):2052-2059.

[3] 彭昱东,孟凯,官红权,等. 心血管病患者感染新型冠状病毒肺炎112例临床特点及转归[J]. 中华心血管病杂志,2020,48(6):450-455.

[4] Zheng YY,Ma YT,Zhang JY,et al. COVID-19 and the cardiovascular system [J]. Nat Rev Cardiol,2020,17(5):259-260.

[5] Yang X,Yu Y,Xu J,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,China:a single-centered,retrospective, observational study[J]. Lancet Respir Med,2020,8(5):475-481.

[6] Zuin M,Rigatelli G,Zuliani G,et al. Arterial hypertension and risk of death in patients with COVID-19 infection:systematic review and meta-analysis[J]. J Infect,2020,81(1):e84-e86.

[7] 中国疾病预防控制中心. 新型冠状病毒肺炎流行病学特征分析[J]. 中华流行病学杂志,2020,41(2):145-151.

[8] Hu Y,Sun J,Dai Z,et al. Prevalence and severity of corona virus disease 2019 (COVID-19):a systematic review and meta-analysis[J]. J Clin Virol , 2020 ,127:104371.

[9] Zhou F,Yu T,Du R,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,China:a retrospective cohort study[J]. Lancet ,2020,395(10229):1054-1062.

[10] Barman HA,Atici A,Sahin I,et al. Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease[J]. Coron Artery Dis,2021,32(5):359-366.

[11] Gu T,Chu Q,Yu Z,et al. History of coronary heart disease increased the mortality rate of patients with COVID-19:a nested case-control study[J]. BMJ Open,2020,10(9):e038976.

[12] Bhatla A,Mayer MM,Adusumalli S,et al. COVID-19 and cardiac arrhythmias[J]. Heart Rhythm,2020,17(9):1439-1444.

[13] Alvarez-Garcia J,Lee S,Gupta A,et al. Prognostic impact of prior heart failure in patients hospitalized with COVID-19[J]. J Am Coll Cardiol,2020,76(20):2334-2348.

[14] Inciardi RM,Adamo M,Lupi L,et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy[J]. Eur Heart J,2020,41(19):1821-1829.

[15] Shi S,Qin M,Shen B,et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan,China[J]. JAMA Cardiol,2020,5(7):802-810.

[16] Huang C,Wang Y,Li X,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet,2020,395(10223):497-506.

[17] Wang D,Hu B,Hu C,et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J]. JAMA,2020,323(11):1061-1069.

[18] Gopinathannair R,Merchant FM,Lakkireddy DR,et al. COVID-19 and cardiac arrhythmias:a global perspective on arrhythmia characteristics and management strategies[J]. J Interv Card Electrophysiol,2020,59(2):329-336.

[19] Kochav SM,Coromilas E,Nalbandian A,et al. Cardiac arrhythmias in COVID-19 infection[J]. Circ Arrhythm Electrophysiol,2020,13(6):e008719.

[20] Zhang Y,Coats AJS,Zheng Z,et al. Management of heart failure patients with COVID-19:a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail,2020,22(6):941-956.

[21] Bangalore S,Sharma A,Slotwiner A,et al. ST-segment elevation in patients with Covid-19—A case series[J]. N Engl J Med,2020,382(25):2478-2480.

[22] Stefanini GG,Montorfano M,Trabattoni D,et al. ST-elevation myocardial infarction in patients with COVID-19:clinical and angiographic outcomes[J]. Circulation,2020,141(25):2113-2116.

[23] Inciardi RM,Lupi L,Zaccone G,et al. Cardiac involvement in a patient with coronavirus disease 2019(COVID-19)[J]. JAMA Cardiol,2020,5(7):819-824.

[24] Hua A,O’Gallagher K,Sado D,et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19[J]. Eur Heart J,2020,41(22):2130.

[25] Zeng JH,Liu YX,Yuan J,et al. First case of COVID-19 complicated with fulminant myocarditis:a case report and insights[J]. Infection,2020,48(5):773-777.

[26] Li Y,Yu Y,Chen S,et al. Corticosteroids and intravenous immunoglobulin in pediatric myocarditis:a meta-analysis[J]. Front Pediatr,2019,7:342.

[27] Siripanthong B,Nazarian S,Muser D,et al. Recognizing COVID-19-related myocarditis:the possible pathophysiology and proposed guideline for diagnosis and management[J]. Heart Rhythm,2020,17(9):1463-1471.

[28] Peretto G,Sala S,Rizzo S,et al. Ventricular arrhythmias in myocarditis:characterization and relationships with myocardial inflammation[J]. J Am Coll Cardiol,2020,75(9):1046-1057.

[29] Chen T,Wu D,Chen H,et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019:retrospective study[J]. BMJ,2020,368:m1091.

[30] Rey JR,Caro-Codón J,Rosillo SO,et al. Heart failure in COVID-19 patients:prevalence,incidence and prognostic implications[J]. Eur J Heart Fail,2020,22(12):2205-2215.

[31] Lei Y,Zhang J,Schiavon CR,et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2[J]. Circ Res,2021,128(9):1323-1326.

[32] Kuba K,Imai Y,Rao S,et al. A crucial role of angiotensin converting enzyme 2(ACE2) in SARS coronavirus-induced lung injury[J]. Nat Med,2005,11(8):875-879.

[33] Epelman S,Shrestha K,Troughton RW,et al. Soluble angiotensin-converting enzyme 2 in human heart failure:relation with myocardial function and clinical outcomes[J]. J Card Fail,2009,15(7):565-571.

[34] Furuhashi M,Moniwa N,Mita T,et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan,an angiotensin Ⅱ receptor blocker[J]. Am J Hypertens,2015,28(1):15-21.

[35] Zhang H,Penninger JM,Li Y,et al. Angiotensin-converting enzyme 2(ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target[J]. Intensive Care Med,2020,46(4):586-590.

[36] Meng J,Xiao G,Zhang J,et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension[J]. Emerg Microbes Infect,2020,9(1):757-760.

[37] Lopes RD,Macedo AVS,de Barros E Silva PGM,et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensinⅡ receptor blockers on days alive and out of the hospital in patients admitted with COVID-19:a randomized clinical trial[J]. JAMA,2021,325(3):254-264.

[38] 中华医学会心血管分会,中华心血管病杂志编辑委员会. 关于新型冠状病毒肺炎与RAS抑制剂治疗心血管疾病的科学声明[J]. 中华心血管病杂志,2020,48(7):565-566.

更新日期/Last Update: 2021-12-06